AstraZeneca's Combo Limits Lung Cancer Progression in Late-Stage Trial

By Reuters Staff

October 30, 2019

(Reuters) - AstraZeneca Plc said on Monday that its cancer drug Imfinzi (durvalumab) plus chemotherapy, with or without the anti-CTLA4 antibody tremelimumab, helped curb progression of treatment-naive metastatic non-small-cell lung cancer in a late-stage study.

In the randomized Poseidon trial, patients received either Imfinzi plus platinum-based chemotherapy; Imfinzi, tremelimumab and chemotherapy; or chemotherapy alone. The trial excluded patients with a mutation in the epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) gene.

"The trial met a primary endpoint by showing a statistically significant and clinically meaningful improvement in the final progression-free survival analysis in patients treated with the combination of Imfinzi and a broad choice of five standard-of-care platinum-based chemotherapy options vs. chemotherapy alone," the company said. "The triple combination of Imfinzi plus tremelimumab and chemotherapy also demonstrated a statistically significant and clinically meaningful PFS improvement vs. chemotherapy alone as a key secondary endpoint."

The triple combination delivered a broadly similar safety profile to the Imfinzi and chemotherapy combination and did not result in increased discontinuation of therapy, AstraZeneca said.

The trial will continue to assess the additional primary endpoint of overall survival with data anticipated in 2020, the company said.